|
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 136.64 USD | -2.10% |
|
-0.55% | +10.26% |
| 12-10 | This Is Decision Day | |
| 12-10 | Analyst recommendations: Abbvie, Biogen, PepsiCo, Eli Lilly, Netflix… |
| Capitalization | 76.83B 65.45B 61.14B 57.53B 106B 6,959B 116B 714B 277B 3,280B 288B 282B 11,968B | P/E ratio 2026 * |
27.9x | P/E ratio 2027 * | 24.7x |
|---|---|---|---|---|---|
| Enterprise value | 87.07B 74.18B 69.29B 65.19B 120B 7,886B 131B 809B 314B 3,717B 327B 320B 13,563B | EV / Sales 2026 * |
4.6x | EV / Sales 2027 * | 4.29x |
| Free-Float |
58.55% | Yield 2026 * |
1.63% | Yield 2027 * | 1.69% |
Last Transcript: Emerson Electric Co.
| 1 day | -2.10% | ||
| 1 week | -0.55% | ||
| Current month | +2.44% | ||
| 1 month | +6.37% | ||
| 3 months | +1.14% | ||
| 6 months | +8.84% | ||
| Current year | +10.26% |
| 1 week | 134.04 | 140.85 | |
| 1 month | 123.38 | 140.85 | |
| Current year | 90.06 | 150.27 | |
| 1 year | 90.06 | 150.27 | |
| 3 years | 76.94 | 150.27 | |
| 5 years | 72.4 | 150.27 | |
| 10 years | 37.75 | 150.27 |
| Manager | Title | Age | Since |
|---|---|---|---|
| Chief Executive Officer | 56 | 2021-02-04 | |
Michael Baughman
DFI | Director of Finance/CFO | 60 | 2023-05-09 |
Peter Zornio
CTO | Chief Tech/Sci/R&D Officer | 62 | 2022-11-28 |
| Director | Title | Age | Since |
|---|---|---|---|
Joshua Bolten
BRD | Director/Board Member | 71 | 2012-02-08 |
Matt Levatich
BRD | Director/Board Member | 60 | 2012-08-06 |
James Turley
CHM | Chairman | 69 | 2021-05-04 |
| Change | 5d. change | 1-year change | 3-years change | Capi.($) | ||
|---|---|---|---|---|---|---|
| -2.10% | -0.55% | +4.95% | +39.33% | 76.83B | ||
| -0.69% | +1.76% | +24.12% | +76.15% | 217B | ||
| -1.57% | -0.04% | -3.80% | +66.90% | 155B | ||
| -5.25% | -1.68% | -6.75% | +102.87% | 129B | ||
| -0.74% | -4.19% | +121.75% | +221.78% | 77.79B | ||
| -1.62% | -8.54% | +20.13% | +160.00% | 71.95B | ||
| -9.73% | -14.68% | +28.22% | +1,045.38% | 61.66B | ||
| -1.03% | +0.97% | +7.66% | +40.64% | 46.44B | ||
| -1.91% | +0.22% | +36.33% | +49.11% | 45.49B | ||
| +2.00% | +6.04% | -14.12% | +38.36% | 38.34B | ||
| Average | -2.26% | -2.14% | +21.85% | +184.05% | 91.95B | |
| Weighted average by Cap. | -2.24% | -1.61% | +19.87% | +154.43% |
| 2026 * | 2027 * | |
|---|---|---|
| Net sales | 18.92B 16.12B 15.06B 14.17B 26.08B 1,714B 28.49B 176B 68.17B 808B 71B 69.5B 2,947B | 19.91B 16.96B 15.84B 14.91B 27.44B 1,803B 29.98B 185B 71.73B 850B 74.7B 73.13B 3,101B |
| Net income | 2.76B 2.35B 2.19B 2.06B 3.8B 250B 4.15B 25.61B 9.93B 118B 10.34B 10.13B 429B | 3.09B 2.63B 2.46B 2.31B 4.25B 280B 4.65B 28.67B 11.12B 132B 11.58B 11.34B 481B |
| Net Debt | 10.24B 8.72B 8.15B 7.67B 14.11B 927B 15.42B 95.1B 36.89B 437B 38.42B 37.61B 1,595B | 8.48B 7.23B 6.75B 6.35B 11.69B 768B 12.77B 78.79B 30.56B 362B 31.83B 31.16B 1,321B |
| Date | Price | Change | Volume |
|---|---|---|---|
| 25-12-12 | 136.64 $ | -2.10% | 2,240,163 |
| 25-12-11 | 139.57 $ | +1.87% | 2,281,565 |
| 25-12-10 | 137.01 $ | +1.30% | 2,651,336 |
| 25-12-09 | 135.25 $ | -0.50% | 1,646,472 |
| 25-12-08 | 135.93 $ | -1.06% | 2,541,116 |
Delayed Quote Nyse, December 12, 2025 at 04:00 pm
More quotesTrader
This super rating is the result of a weighted average of the rankings based on the following ratings: Global Valuation (Composite), EPS Revisions (4 months), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Investor
This super composite rating is the result of a weighted average of the rankings based on the following ratings: Fundamentals (Composite), Global Valuation (Composite), EPS Revisions (1 year), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Global
This composite rating is the result of an average of the rankings based on the following ratings: Fundamentals (Composite), Valuation (Composite), Financial Estimates Revisions (Composite), Consensus (Composite), and Visibility (Composite). The company must be covered by at least 4 of these 5 ratings for the calculation to be performed. We recommend that you carefully review the associated descriptions.
Quality
This composite rating is the result of an average of the rankings based on the following ratings: Capital Efficiency (Composite), Quality of Financial Reporting (Composite), and Financial Health (Composite). The company must be covered by at least 2 of these 3 ratings for the calculation to be performed. We recommend that you carefully review the associated descriptions.

Quarterly revenue - Rate of surprise
- Stock Market
- Equities
- EMR Stock
Select your edition
All financial news and data tailored to specific country editions
MarketScreener is also available in this country: United States.
Switch edition















